Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Oxygen therapy for COPD is a treatment used to increase the oxygen in your lungs and bloodstream. Research suggests that people with chronic obstructive pulmonary disease (COPD) who use oxygen may ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 52 weeks, patients receiving dupilumab vs. placebo ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Priority Review granted based on positive results from two Phase 3 trials If approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more ...

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

“Emphysema is usually a description of images — CT scan or X-ray — and is only one part of the disease of COPD,” says Uddalak Majumdar, MD, pulmonologist at the Cleveland Clinic in Ohio. COPD is ...